It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chronic stress is a known risk factor for breast cancer, yet the underlying mechanisms are unclear. This study explores the potential involvement of microbial and metabolic signals in chronic stress-promoted breast cancer progression, revealing that reduced abundances of Blautia and its metabolite acetate may contribute to this process. Treatment with Blautia and acetate increases antitumor responses of CD8+ T cells and reverses stress-promoted breast cancer progression in female mice. Patients with depression exhibit lower abundances of Blautia and acetate, and breast cancer female patients with depression display lower abundances of acetate, decreased numbers of tumor-infiltrating CD8+ T cells, and an increased risk of metastasis. These results suggest that Blautia-derived acetate plays a crucial role in modulating the immune response to breast cancer, and its reduction may contribute to chronic stress-promoted cancer progression. Our findings advance the understanding of microbial and metabolic signals implicated in cancer in patients with depression and may provide therapeutic options for female patients with breast cancer and depression.
Chronic stress can promote breast cancer progression. Here the authors show that a reduction in the levels of Blautia and its metabolite acetate contributes to chronic stress-promoted breast cancer progression, associated with decreased CD8 + T cell anti-tumor immunity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Southern Medical University, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
2 China Pharmaceutical University, State Key Laboratory of Natural Medicines, Jiangsu Province Key Laboratory of Drug Metabolism, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793); Shenzhen Luohu People’s Hospital, Department of Pharmacy, Shenzhen, China (GRID:grid.477848.0)
3 Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
4 Southern Medical University, Breast Center, Department of General Surgery, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
5 China Pharmaceutical University, State Key Laboratory of Natural Medicines, Jiangsu Province Key Laboratory of Drug Metabolism, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793)